US Patent

US10098863 — Fumarate esters

Method of Use · Assigned to Banner Life Sciences LLC · Expires 2035-02-27 · 9y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions and methods for treating multiple sclerosis subjects with fumarate esters, including oral delayed release dosage forms.

USPTO Abstract

Described herein are pharmaceutical compositions comprising one or more fumarate esters, processes for making the same, and compositions and methods for treating multiple sclerosis subjects with the compositions. In particular, oral pharmaceutical compositions comprising fumarate esters in liquid vehicles are described. One embodiment is an oral delayed release pharmaceutical dosage form comprising a soft capsule encapsulating an immediate releasing liquid comprising one or more fumarate esters.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1384 monomethyl-fumarate

Patent Metadata

Patent number
US10098863
Jurisdiction
US
Classification
Method of Use
Expires
2035-02-27
Drug substance claim
No
Drug product claim
Yes
Assignee
Banner Life Sciences LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.